Versão HTML básica
390
Nucci M
Rev Bras Hematol Hemoter. 2012;34(5):383-91
31. UllmannAJ, Lipton JH, Vesole DH, Chandrasekar P, LangstonA, Tarantolo
SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-
versus-host disease. N Engl J Med. 2007;356(4):335-47. Comment in: N
Engl J Med. 2007;356(4):409-11. Curr Infect Dis Rep. 2007;9(6):445-6. N
Engl J Med. 2007;356(21):2215; author reply 2215-8.
32. Aguado JM, Varo E, Usetti P, Pozo JC, Moreno A, Catalán M, Len O,
Blanes M, Solé A, Muñoz P, Montejo M, Jerez V, Solé A, Aragón C,
Fernández-Sabe N, del Pozo J, Robles J, Montejo J, Valerio M, Bouza E,
Fernández S, Baños I, Segovia J, Rey T; TOSCANA Study Group. Safety
of anidulafungin in solid organ transplant recipients. Liver Transpl.
2012;18(6):680-5.
33. Krishnan-Natesan S, Manavathu EK, Cutright JL, Chandrasekar PH.
Efficacy of anidulafungin, caspofungin and fluconazole in the early phase
of infection in a neutropenic murine invasive candidiasis model. Int J
Antimicrob Agents. 2010;36(1):33-6.
34. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar
D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ;
Anidulafungin Study Group. Anidulafungin versus fluconazole for
invasive candidiasis. N Engl J Med. 2007;356(24):2472-82. Comment
in: N Engl J Med. 2007;357(13):1347; author reply 1348. N Engl J Med.
2007; 356(24):2525-6. ACP J Club. 2008;148(1):15.
35. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et
al. Micafungin versus caspofungin for treatment of candidemia and other
forms of invasive candidiasis. Clin Infect Dis. 2007;45:883-93.
36. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-
Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect
J; Caspofungin Invasive Candidiasis Study Group. Comparison of
caspofungin and amphotericin B for invasive candidiasis. N Engl J Med.
2002;347(25):2020-9.Comment in: N Engl J Med. 2002;347(25):2070-2.
ACP J Club. 2003;139(1):15. N Engl J Med. 2003;348(13):1287-8;
author reply 1287-8.
37. Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ,
Herbrecht R, Ruiz-Palacios G, Young JA, Baddley JW, Strohmaier KM,
Tucker KA, Taylor AF, Kartsonis NA, Colombo A, Nucci M, Queiroz-
Telles F, Mayer J, Beltran S, Herbrecht R, Cornely O, Just-Nuebling G,
Digumarti R, Talwar D, Viale P, Carosi G, Rozentale B, Ruiz-Palacios G,
Andrade Perez J, Ringstad J, Sosa N, Barbosa S, Moreno R, Streinu-Cercel
A, Tulbure D, Grintescu I, Wang JH, Chen YC, Betts R, Cecil J, Morris M,
Bedimo R, Young J, Brown J, Baddley J, Gareca M, Graham D, Barron
M, Mullane K, Reinhardt J, Jones R, Cleary J. Caspofungin High-Dose
Study Group. AMulticenter, double-blind trial of a high-dose caspofungin
treatment regimenversus a standard caspofungin treatment regimen for adult
patients with invasive candidiasis. Clin Infect Dis. 2009;48(12):1676-84.
Comment in: Antimicrob Agents Chemother. 2011; 55(7):3643-4.
38. Maertens JA, Madero L, Reilly AF, Lehrnbecher T, Groll AH, Jafri HS,
Green M, Nania JJ, Bourque MR, Wise BA, Strohmaier KM, Taylor AF,
Kartsonis NA, Chow JW, Arndt CA, DePauw BE, Walsh TJ, Maertens J,
Berthold F, Groll A, Lehrnbecher T, Simon A, Castel Sanchez P, Garcia
Miguel P, Madero-Lopez L, Sanchez de Toledo J, Flynn P, Green M, Jafri
H, Nania J, Pulsipher M, Reilly A, Seibel N, Yogev R, de Pauw BE, Arndt
CA, Walsh TJ; Caspofungin Pediatric Study Group. A randomized, double-
blind, multicenter study of caspofungin versus liposomal amphotericin B
for empiric antifungal therapy in pediatric patients with persistent fever and
neutropenia. Pediatr Infect Dis J. 2010;29:415-20. Comment in: Pediatr
Infect Dis J. 2010; 29(10):985-6; author reply 986-7.
39. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR,
Dmoszynska A, et al. Caspofungin versus liposomal amphotericin B
for empirical antifungal therapy in patients with persistent fever and
neutropenia. N Engl J Med. 2004;351(14):1391-402.Comment in: N
Engl J Med. 2004;351(14):1445-7. ACP J Club. 2005;142(2):33. N Engl
J Med. 2005;352(4):410-4; author reply 410-4.
40. de Fabritiis P, Spagnoli A, Di Bartolomeo P, Locasciulli A, Cudillo
L, Milone G, et al. Efficacy of caspofungin as secondary prophylaxis
in patients undergoing allogeneic stem cell transplantation with prior
pulmonary and/or systemic fungal infection. Bone Marrow Transplant.
2007;40(3):245-9.
41. Vehreschild JJ, Sieniawski M, Reuter S, Arenz D, Reichert D, Maertens
J, et al. Efficacy of caspofungin and itraconazole as secondary antifungal
prophylaxis: analysis of data from a multinational case registry. Int J
Antimicrob Agents. 2009;34(5):446-50.
42. Marr KA, Schlamm H, Rottinghaus S, Jagannatha EJ, Bow JR, Wingard
P, Pappas R, Herbrecht TJ, Walsh J. Maertens, and the Mycoses Study
Group. A randomised, double-blind study of combination antifungal
therapy with voriconazole and anidulafungin versus voriconazole
monotherapyfor primary treatment of invasive aspergillosis [Abstract].
22nd European Congress of Clinical 416 Microbiology and Infectious
Diseases, abstr LB 2812.
43. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and
consequences for treatment. Am J Med. 2012;125(1 Suppl):S3-13.
44. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME,
et al. Prolonged fluconazole prophylaxis is associated with persistent
protection against candidiasis-related death in allogeneic marrow
transplant recipients: long-term follow-up of a randomized, placebo-
controlled trial. Blood. 2000;96(6):2055-61.
45. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou
S. Antifungal prophylaxis for severely neutropenic chemotherapy
recipients: a meta analysis of randomized-controlled clinical trials.
Cancer. 2002;94(12):3230-46.
46. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH,
Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh
TJ; National Institute of Allergy and Infectious Diseases Mycoses Study
Group. Micafungin versus fluconazole for prophylaxis against invasive
fungal infections during neutropenia in patients undergoing hematopoietic
stem cell transplantation. Clin Infect Dis. 2004;39(10):1407-16.Comment
in: Clin Infect Dis. 2005;40(11):1699; author reply 1699-701.
47. Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki
M, Miller PJ, Ribaud P, Schlamm HT, Solano C, Cook G, Abecasis M,
Afanasyev B, Akan H, Anagnostopoulos A, Batlle M, Bofarull RM,
Bordigoni P, Bourhis JH, Bow E, Cetkovsky P, Cordonnier C, Crawley C,
de la Camara R, Eser B, Espigado E, El Hadad E, de la Serna J, Faucher C,
Gratwohl A, Haider S, Hunter C, Larverdière M, Leprêtre S, Liakopoulou
E, Maschan A, Mayer J, Milpied N, Narayanan S, Parker A, Passweg
J, Perez J, Peristeri I, Pimentel P, Potter M, Reman O, Rovira M, Saad
M, Sanz M, Smith M, Vazquez L, Wilson K.; IMPROVIT Study Group.
Voriconazole versus itraconazole for antifungal prophylaxis following
allogeneic haematopoietic stem-cell transplantation. Br J Haematol.
2011;155(3):318-27.
48. Marr KA, Bow E, Chiller T, Maschmeyer G, Ribaud P, Segal B, Steinbach
W, Wingard JR, Nucci M; Center for International Blood and Marrow
Transplant Research; National Marrow Donor Program; European
Blood and Marrow Transplant Group; American Society of Blood
and Marrow Transplantation; Canadian Blood and Marrow Transplant
Group; Infectious Disease Society of America; Society for Healthcare
Epidemiology of America; Association of Medical Microbiology and
Infectious Diseases Canada; Centers for Disease Control and Prevention.
Fungal infection prevention after hematopoietic cell transplantation.
Bone Marrow Transplant. 2009;44(8):483-7.
49. Nucci M, Nouer SA, Grazziutti M, Kumar NS, Barlogie B, Anaissie E.
Probable invasive aspergillosis without prespecified radiologic findings:
proposal for inclusion of a new category of aspergillosis and implications
for studying novel therapies. Clin Infect Dis. 2010;51(11):1273-80.
Comment in: Clin Infect Dis. 2010;51(11):1281-3
50. Nucci M, Anaissie E. Infections in patients with multiple myeloma
in the era of high-dose therapy and novel agents. Clin Infect Dis.
2009;49(8):1211-25.